Your browser doesn't support javascript.
loading
Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts.
Tiendrebeogo, Thierry; Malateste, Karen; Poda, Armel; Minga, Albert; Messou, Eugene; Chenal, Henri; Ezechi, Oliver; Ekouevi, Didier K; Ofotokun, Igho; Jaquet, Antoine.
Afiliação
  • Tiendrebeogo T; National Institute for Health and Medical Research UMR 1219, Research Institute for Sustainable Development EMR 271, Bordeaux Population Health Research Centre, University of Bordeaux, Bordeaux, France.
  • Malateste K; National Institute for Health and Medical Research UMR 1219, Research Institute for Sustainable Development EMR 271, Bordeaux Population Health Research Centre, University of Bordeaux, Bordeaux, France.
  • Poda A; Department of Infectious Diseases, Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.
  • Minga A; Centre médical de Suivi des Donneurs de Sang, Centre National de Transfusion Sanguine Côte d'Ivoire, Abidjan, Côte d'Ivoire.
  • Messou E; Centre de Prise en charge de Recherche et de Formation, Abidjan, Côte d'Ivoire.
  • Chenal H; Programme PACCI/ANRS Research Center, Abidjan, Cote d'Ivoire.
  • Ezechi O; Département de Dermatologie et d'Infectiologie, Unite de Formation et de Recherche des Sciences Médicales, Université Félix Houphouët Boigny, Abidjan, Côte d'Ivoire.
  • Ekouevi DK; Virology Laboratory, Integrated Centre for Bioclinical Research in Abidjan, Abidjan, Côte d'Ivoire.
  • Ofotokun I; Office of the Central Secretariat, Nigeria Institute for Medical Research, Lagos, Nigeria.
  • Jaquet A; National Institute for Health and Medical Research UMR 1219, Research Institute for Sustainable Development EMR 271, Bordeaux Population Health Research Centre, University of Bordeaux, Bordeaux, France.
Open Forum Infect Dis ; 11(5): ofae139, 2024 May.
Article em En | MEDLINE | ID: mdl-38680609
ABSTRACT
Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with persisting disparities, according to contributing HIV clinics. Key factors facilitating dolutegravir switch were male sex, age <50 years, viral suppression, and regimens not based on protease inhibitors.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2024 Tipo de documento: Article